Immune cells in lung disease and how they could guide immunotherapy
Immune Cells Role in Lung Cancer and Their Use in Anticancer Immunotherapies and Inflammatory Lung Disease
This project sees if immune cell profiling from blood can explain why people with lung cancer, sarcoidosis, or COPD respond differently to immunotherapy or develop chronic lung inflammation.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 425 (estimated) |
| Ages | N/A to 80 Years |
| Sex | All |
| Sponsor | Université Catholique de Louvain Academic / other |
| Drugs / interventions | prednisone, immunotherapy |
| Locations | 1 site (Brussels) |
| Trial ID | NCT07384897 on ClinicalTrials.gov |
What this trial studies
Researchers will collect peripheral blood (and in some cases bone marrow collected during planned orthopedic surgery) to profile immune cells from people with lung cancer, precancerous lung lesions, sarcoidosis, COPD, and from healthy controls. The study excludes people with acute infection, those on high-dose systemic corticosteroids (>10 mg/day prednisone equivalent), or on chronic immunosuppressive therapy. Immune cell types and signatures will be compared between disease groups and controls to identify patterns linked to inflammation, cancer progression, or resistance to immunotherapy. The findings aim to generate biomarkers and hypotheses that could guide more personalized treatments in future trials.
Who should consider this trial
Good fit: Ideal candidates include adults with lung cancer or precancerous lung lesions, untreated patients with sarcoidosis or COPD, eligible children with genetically confirmed CGD (≥10 kg), healthy control volunteers, and adults scheduled for orthopedic surgery who can provide bone marrow, provided they can give informed consent and are not on high-dose steroids or immunosuppressants.
Not a fit: Patients currently on systemic immunosuppressive therapy or high-dose corticosteroids, those with an acute infection, or those unwilling/unable to consent are excluded and are unlikely to benefit from this research-focused protocol.
Why it matters
Potential benefit: If successful, this work could identify immune-cell patterns that help doctors choose or design more effective, personalized immunotherapies and treatments for lung diseases.
How similar studies have performed: Similar immune-profiling studies have shown promise in identifying biomarkers of immunotherapy response and inflammation but have not yet produced universally reliable clinical tests.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of lung cancer * Presence of precancerous lung lesions * Patients with a chronic inflammatory lung disease (sarcoidosis or chronic obstructive pulmonary disease \[COPD\]) prior to any treatment * Control group: individuals without known lung disease * Children and adolescents weighing ≥ 10 kg with genetically confirmed chronic granulomatous disease (CGD) * Adults scheduled to undergo orthopedic surgery during which a bone marrow sample will be collected Exclusion Criteria: * Systemic corticosteroid therapy \> 10 mg/day prednisone (or equivalent) * Acute infection at the time of inclusion * Refusal or inability to provide informed consent (or assent, when applicable) * Chronic inflammatory lung disease currently treated with immunosuppressive therapy
Where this trial is running
Brussels
- Cliniques universitaires saint Luc — Brussels, Belgium (Recruiting)
Study contacts
- Study coordinator: Frank Aboubakar Nana, MD; PhD
- Email: frank.aboubakar@saintluc.uclouvain.be
- Phone: 0032 2 764 85 19
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.